Provided by Tiger Fintech (Singapore) Pte. Ltd.

PagerDuty, Inc.

14.74
-0.3500-2.32%
Post-market: 14.740.00000.00%16:20 EDT
Volume:1.34M
Turnover:19.87M
Market Cap:1.34B
PE:-24.90
High:15.21
Open:15.07
Low:14.66
Close:15.09
Loading ...

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

GlobeNewswire
·
09 Dec 2024

BRIEF-Pagerduty Appoints Sarah Franklin To Board Of Directors

Reuters
·
06 Dec 2024

PagerDuty Appoints Sarah Franklin to Board of Directors

THOMSON REUTERS
·
06 Dec 2024

PagerDuty Appoints Sarah Franklin to Board of Directors

Business Wire
·
06 Dec 2024

Inseego Declines 24% in a Month: Buy, Sell or Hold the Stock?

Zacks
·
06 Dec 2024

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group

GlobeNewswire
·
05 Dec 2024

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

PR Newswire
·
05 Dec 2024

Amazon Advances AI Push With New Models and Partnerships; Stock Up 25.5% YTD

GuruFocus.com
·
05 Dec 2024

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

GlobeNewswire
·
04 Dec 2024

PagerDuty, AWS Collaborate to Bring New AI, Automation Features to PagerDuty Advance

MT Newswires Live
·
04 Dec 2024

PagerDuty announces new generative AI, automation features at AWS re:Invent

TIPRANKS
·
04 Dec 2024

PagerDuty and AWS Deliver on the Promise of Generative AI for Business and Operational Resiliency

Business Wire
·
04 Dec 2024

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

GlobeNewswire
·
03 Dec 2024

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

GlobeNewswire
·
02 Dec 2024

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

GlobeNewswire
·
02 Dec 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

GlobeNewswire
·
02 Dec 2024

BRIEF-FDA Says Baxter Is Correcting Minicap Extended Life PD Transfer Sets

Reuters
·
30 Nov 2024

Potential Risks Loom Over Pagerduty’s Financial Outlook: Key Takeaways from the Latest 10-Q Report

TIPRANKS
·
29 Nov 2024

PagerDuty price target raised to $20 from $19 at Morgan Stanley

TipRanks
·
28 Nov 2024

PagerDuty Third Quarter 2025 Earnings: Beats Expectations

Simply Wall St.
·
28 Nov 2024